Loading…
3 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Total Sharm | Healthcare Services | 17.7% | 72nd pct | 268 |
| Total Sharm Piatsa | Healthcare Services | 13.3% | 59th pct | 268 |
| Aptos | Medical Devices | -3.9% | 10th pct | 39 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | Aptos | Total Sharm | Total Sharm Piatsa |
|---|---|---|---|
| Margins | |||
| Gross Margin | 57.1% | 50.8% | 66.6% |
| EBITDA Margin | -3.9% | 17.7% | 13.3% |
| EBITDAR | -2,515 | 1,697 | 155 |
| EBITDAR Margin | -3.9% | 17.7% | 13.3% |
| EBIT Margin | -7.4% | 11.6% | 1.2% |
| Net Profit Margin | -9.1% | 9.8% | 2.3% |
| Operating Expense % of Sales | 61.5% | 33.1% | 53.3% |
| Returns | |||
| Return on Assets (ROA) | -8.2% | 11.2% | 1.6% |
| Return on Equity (ROE) | -11.3% | 15.2% | 1.7% |
| ROIC [EBIT / Invested Capital] | -8.4% | 14.4% | 1.1% |
| Leverage & debt balances | |||
| Debt-to-Assets | 13.4% | 24.4% | 0.0% |
| Debt-to-Equity | 0.18x | 0.33x | 0.00x |
| Debt-to-EBITDA | N/A | 1.21x | 0.00x |
| Equity-to-Assets | 72.9% | 73.5% | 94.9% |
| Net Debt | 4,354 | 1,551 | -364 |
| Cash & Equivalents | 5,276 | 503 | 364 |
| Total Debt | 9,630 | 2,054 | N/A |
| Liquidity & working capital | |||
| Current Ratio | 1.55x | 8.36x | 6.58x |
| Quick Ratio | 0.97x | 8.36x | 6.58x |
| Cash Ratio | 0.28x | 2.81x | 4.25x |
| Total Current Assets | 29,569 | 1,498 | 563 |
| Total Current Liabilities | 19,134 | 179 | 86 |
| Inventory | 11,009 | N/A | N/A |
| Trade Receivables | 9,699 | 102 | N/A |
| Trade Payables | 8,651 | 179 | 86 |
| Net Working Capital | 10,435 | 1,319 | 478 |
| Net Working Capital % of Revenue | 16.1% | 13.7% | 40.9% |
| Trade Working Capital | 12,057 | -77 | -86 |
| Trade Working Capital % of Revenue | 18.6% | -0.8% | -7.3% |
| Change in Trade Working Capital | N/A | N/A | N/A |
| Turnover & efficiency | |||
| Inventory Turnover | 2.53x | N/A | N/A |
| Days Inventory Outstanding (DIO) | 144.1 | N/A | N/A |
| Receivables Turnover | 6.70x | 94.12x | N/A |
| Days Sales Outstanding (DSO) | 54.5 | 3.9 | N/A |
| Payables Turnover | 3.22x | 26.38x | 4.57x |
| Days Payable Outstanding (DPO) | 113.2 | 13.8 | 79.9 |
| Cash Conversion Cycle | 85.4 days | -10.0 days | -79.9 days |
| Asset Turnover | 0.90x | 1.14x | 0.69x |
| Cash flow & dividends | |||
| Operating Cash Flow | 4,358 | 369 | 294 |
| Free Cash Flow (OCF − Capex proxy) | 339 | 369 | 294 |
| Cash Conversion (OCF / EBITDA) | N/A | 21.8% | 189.4% |
| Dividends Declared | 529 | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A |